NORCROSS, Ga., May 31, 2017 (GLOBE NEWSWIRE) -- MANNHEIM, Germany (EFI BOOTH 10) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that ATC A.S. has been awarded a contract with the Turkish Ministry of Health for bone marrow registry HLA typing results, and will be using the Immucor MIA FORA® NGS FLEX HLA Typing solution. ATC has constructed a fully functional HLA typing laboratory in Ankara, Turkey, and testing is expected to begin in early summer. The awarded tender is for a period of three years, with more than 300,000 samples forecasted to be typed during this time.
Turan Torunn, ATC CEO, stated “We are very pleased to be the service provider for the HLA Typing tender from the Turkish Ministry of Health and look forward to providing high quality and timely results for the Turkish Bone Marrow Registry. Immucor’s MIA FORA NGS FLEX HLA Typing solution was chosen due to its flexibility, workflow, and high quality results. Immucor has been a fantastic partner in setting up the laboratory and training our staff.”
Keith Chaitoff, Immucor Chief Marketing Officer and Vice President International Commercial Operations, added, “Immucor is very excited to partner with ATC on this important project. The flexibility of the MIA FORA assay to be used in high volume automated registry settings or lower volume clinical laboratories is a key capability of the product, while producing the highest quality results that make a difference in the lives of patients and their families. We look forward to a long relationship with ATC and the Turkish registry.”
Immucor’s MIA FORA NGS FLEX HLA Typing Assay is available as 5, 6, 9 and 11 gene kits with efficient laboratory workflow that means sample preparation to sequencing in less than 24 hours. The MIA FORA NGS FLEX kits are partnered with the MIA FORA FLEX 3.0 software that streamlines data analysis and is compatible with both Linux and Windows-based servers.
The MIA FORA NGS FLEX offering provides superior whole gene coverage of all major HLA gene regions; partial coverage for exon 6 and intron 1; and all exons and introns between exons 2 and 4 for HLA-DPB, including whole gene coverage for HLA-A,B, C, DPA1, DQA1, and DQB1; all exons and introns for HLA-DRB1,3,4,5 except 1. This broad coverage minimizes ambiguities, in particular for DRB1,3,4,5, which uses a unique approach to primer design to maximize coverage.
The MIA FORA NGS FLEX HLA Typing Assay has been validated on the Illumina MiSeq and MiniSeq platforms using multiple flow cell options. The MIA FORA NGS FLEX offering is available as Research Use Only (RUO) in the United States and is CE Marked.
Complemented by the LIFECODES typing and HLA antibody products, and kSORT post-transplant surveillance solutions, Immucor is well-positioned to meet the needs of transplant laboratories, clinicians, and patients today and well into the future.
About Immucor
Founded in 1982, Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Our mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable. With the right match, we can transform a life together. For more information on Immucor, please visit our website at www.immucor.com.